CH Biotech R&D Co., Ltd.(TW:6534)
NT$85.20-0.80 (-0.93%)
TW:6534
CH Biotech R&D Co., Ltd. financials statements
NT$85.20
At close:-0.80 (-0.93%)
CH Biotech R&D Co., Ltd. (6534) Ratios
CH Biotech R&D Co., Ltd. Ratios
TW:6534's free cash flow for Q2 2026 was NT$404.64M. For the 2026 fiscal year, TW:6534's free cash flow was decreased by NT$-38.43M and operating cash flow was NT$443.07M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.21 | 1.32 | 1.40 | 1.72 | 1.24 |
| Quick Ratio | 1.00 | 1.14 | 1.27 | 1.34 | 1.04 |
| Cash Ratio | 0.55 | 0.74 | 1.07 | 1.13 | 0.61 |
| Solvency Ratio | 0.76 | 0.68 | 0.56 | 0.55 | 0.30 |
| Operating Cash Flow Ratio | 0.82 | 0.83 | 0.75 | 1.50 | 0.50 |
| Short-Term Operating Cash Flow Coverage | 1.25 | 1.36 | 1.15 | 2.91 | 0.80 |
| Net Current Asset Value | NT$ -16.88M | NT$ -129.84M | NT$ 106.37M | NT$ -303.91M | NT$ -651.00M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.21 | 0.23 | 0.28 | 0.37 |
| Debt-to-Equity Ratio | 0.25 | 0.28 | 0.34 | 0.43 | 0.65 |
| Debt-to-Capital Ratio | 0.20 | 0.22 | 0.25 | 0.30 | 0.39 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.07 | 0.00 | 0.16 | 0.23 |
| Financial Leverage Ratio | 1.33 | 1.37 | 1.45 | 1.53 | 1.76 |
| Debt Service Coverage Ratio | 1.50 | 1.65 | 1.09 | 2.42 | 1.17 |
| Interest Coverage Ratio | 36.73 | 36.17 | 33.66 | 34.62 | 26.87 |
| Debt to Market Cap | 0.05 | 0.07 | 0.07 | 0.06 | 0.09 |
| Interest Debt Per Share | 6.63 | 7.38 | 8.86 | 9.39 | 11.70 |
| Net Debt to EBITDA | 0.32 | 0.34 | -0.12 | 0.51 | 1.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 74.53% | 83.44% | 83.18% | 79.11% | 83.25% |
| EBIT Margin | 34.25% | 37.17% | 39.33% | 40.62% | 36.68% |
| EBITDA Margin | 46.02% | 48.77% | 50.27% | 50.36% | 46.17% |
| Operating Profit Margin | 34.25% | 33.15% | 37.35% | 40.59% | 36.67% |
| Pretax Profit Margin | 31.27% | 36.25% | 38.22% | 39.45% | 35.31% |
| Net Profit Margin | 25.49% | 29.12% | 30.58% | 32.45% | 28.62% |
| Continuous Operations Profit Margin | 25.49% | 29.08% | 30.58% | 32.45% | 28.62% |
| Net Income Per EBT | 81.53% | 80.34% | 80.02% | 82.26% | 81.05% |
| EBT Per EBIT | 91.29% | 109.34% | 102.31% | 97.21% | 96.31% |
| Return on Assets (ROA) | 12.98% | 13.13% | 12.70% | 14.57% | 9.62% |
| Return on Equity (ROE) | 17.27% | 18.00% | 18.38% | 22.29% | 16.92% |
| Return on Capital Employed (ROCE) | 21.84% | 18.18% | 20.45% | 21.34% | 14.94% |
| Return on Invested Capital (ROIC) | 15.16% | 12.78% | 13.43% | 16.02% | 10.64% |
| Return on Tangible Assets | 13.02% | 13.15% | 12.72% | 14.60% | 9.65% |
| Earnings Yield | 5.01% | 5.71% | 5.91% | 4.77% | 2.99% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.07 | 9.97 | 14.28 | 42.44 | 5.56 |
| Payables Turnover | 51.25 | 30.66 | 27.52 | 31.15 | 8.24 |
| Inventory Turnover | 3.02 | 2.31 | 2.14 | 1.69 | 1.66 |
| Fixed Asset Turnover | 0.69 | 0.60 | 0.64 | 0.60 | 0.43 |
| Asset Turnover | 0.51 | 0.45 | 0.42 | 0.45 | 0.34 |
| Working Capital Turnover Ratio | 10.23 | 5.85 | 4.40 | 6.21 | 17.24 |
| Cash Conversion Cycle | 173.89 | 182.46 | 183.11 | 212.89 | 241.72 |
| Days of Sales Outstanding | 60.11 | 36.59 | 25.56 | 8.60 | 65.64 |
| Days of Inventory Outstanding | 120.90 | 157.77 | 170.81 | 216.01 | 220.39 |
| Days of Payables Outstanding | 7.12 | 11.91 | 13.26 | 11.72 | 44.32 |
| Operating Cycle | 181.01 | 194.36 | 196.37 | 224.61 | 286.04 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 5.73 | 5.21 | 6.77 | 7.20 | 2.72 |
| Free Cash Flow Per Share | 4.53 | -0.50 | 5.58 | 5.99 | 1.98 |
| Dividend Paid and CapEx Coverage Ratio | 1.08 | 0.56 | 1.12 | 2.86 | 2.32 |
| Capital Expenditure Coverage Ratio | 4.78 | 0.91 | 5.67 | 5.94 | 3.68 |
| Operating Cash Flow Coverage Ratio | 0.89 | 0.72 | 0.78 | 0.78 | 0.24 |
| Operating Cash Flow to Sales Ratio | 0.32 | 0.33 | 0.44 | 0.49 | 0.26 |
| Free Cash Flow Yield | 5.03% | -0.62% | 6.93% | 5.96% | 1.97% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 19.96 | 17.53 | 16.91 | 20.98 | 33.50 |
| Price-to-Sales (P/S) Ratio | 5.09 | 5.10 | 5.17 | 6.80 | 9.58 |
| Price-to-Book (P/B) Ratio | 3.45 | 3.16 | 3.11 | 4.67 | 5.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 19.87 | -162.08 | 14.43 | 16.78 | 50.70 |
| Price-to-Operating Cash Flow Ratio | 15.71 | 15.51 | 11.89 | 13.96 | 36.91 |
| Price-to-Earnings Growth (PEG) Ratio | -9.20 | -5.56 | -27.00 | 0.35 | 0.18 |
| Enterprise Value Multiple | 11.38 | 10.80 | 10.16 | 14.01 | 22.45 |
| Enterprise Value | 9.53B | 8.62B | 7.74B | 10.12B | 10.56B |
| EV to EBITDA | 11.38 | 10.80 | 10.16 | 14.01 | 22.45 |
| EV to Sales | 5.24 | 5.27 | 5.11 | 7.06 | 10.37 |
| EV to Free Cash Flow | 20.45 | -167.29 | 14.26 | 17.41 | 54.87 |
| EV to Operating Cash Flow | 16.17 | 16.00 | 11.74 | 14.48 | 39.94 |
| Tangible Book Value Per Share | 26.01 | 25.56 | 25.83 | 21.42 | 17.67 |
| Shareholders’ Equity Per Share | 26.12 | 25.61 | 25.89 | 21.50 | 17.75 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | 0.20 | 0.20 | 0.18 | 0.19 |
| Revenue Per Share | 17.69 | 15.83 | 15.56 | 14.77 | 10.49 |
| Net Income Per Share | 4.51 | 4.61 | 4.76 | 4.79 | 3.00 |
| Tax Burden | 0.82 | 0.80 | 0.80 | 0.82 | 0.81 |
| Interest Burden | 0.91 | 0.98 | 0.97 | 0.97 | 0.96 |
| Research & Development to Revenue | 0.22 | 0.22 | 0.20 | 0.19 | 0.22 |
| SG&A to Revenue | 0.27 | 0.28 | 0.26 | 0.24 | 0.26 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.27 | 0.91 | 1.14 | 1.24 | 0.74 |
Currency in TWD
